Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

4

Suggested Citation

Niyomnaitham S., Quan Toh Z., Wongprompitak P., Jansarikit L., Srisutthisamphan K., Sapsutthipas S., Jantraphakorn Y., Mingngamsup N., Licciardi P.V., Chokephaibulkit K. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Human Vaccines and Immunotherapeutics Vol.18 No.6 (2022). doi:10.1080/21645515.2022.2091865 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85049

Availability

Collections